CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that management will participate in the following upcoming investor conferences:<\/p>\n
Live webcasts will be available in the investor section of the company's website at http:\/\/www.vervetx.com<\/a> and will be archived for 60 days following the presentations.<\/p>\n About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The companys initial two programs VERVE-101 and VERVE-201 target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease, in order to durably reduce blood LDL-C levels. VERVE-101 is designed to permanently turn off thePCSK9gene in the liver and is being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat atherosclerotic cardiovascular disease (ASCVD) not at goal on oral therapy. VERVE-201 is designed to permanently turn off theANGPTL3gene in the liver and is initially being developed in homozygous familial hypercholesterolemia (HoFH) and ultimately in patients with ASCVD who have not achieved goal LDL-C with oral therapy and a PCSK9 inhibitor. For more information, please visit http:\/\/www.VerveTx.com<\/a>.<\/p>\n Investor ContactJen RobinsonVerve Therapeutics, Inc.jrobinson@vervetx.com<\/a><\/p>\n Media ContactAshlea Kosikowski1ABashlea@1abmedia.com<\/a><\/p>\n <\/p>\n Read the original post: CAMBRIDGE, Mass., Sept. Continue reading
\nVerve Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"